Abstract data and new results from the EMERALD-1 Study of MORF-057 in ulcerative colitis In EMERALD-1 an open-label, single-arm Phase 2a trial of MORF-057 that enrolled 35 patients with moderate ...

EMERALD-1 is a double-blind phase 3 study that enrolled 616 patients eligible for embolization to treat unresectable HCC. Patients were randomized in 3 groups: the first received the immune ...

There are 3 groups of treatments. Which group you go into depends on when you join the study. You have 1 treatment of high dose radiotherapy. The first to open is group 1. To start with only a few ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study The following represents disclosure information ...